Abstract
PARP inhibitors exploit synthetic lethality in homologous recombination-deficient (HDR) cells and are standard-of-care treatment in newly diagnosed and relapsed epithelial ovarian cancer (EOC). A recent article demonstrated that a second course of olaparib can be safely administered to women with BRCA-mutated EOC. See related article by Morgan et al., p. 2602.
©2023 American Association for Cancer Research.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
BRCA1 Protein / genetics
-
BRCA2 Protein / genetics
-
Carcinoma, Ovarian Epithelial / drug therapy
-
Female
-
Germ Cells
-
Humans
-
Neoplasm Recurrence, Local
-
Ovarian Neoplasms* / drug therapy
-
Ovarian Neoplasms* / genetics
-
Phthalazines / adverse effects
-
Poly(ADP-ribose) Polymerase Inhibitors* / adverse effects
Substances
-
Poly(ADP-ribose) Polymerase Inhibitors
-
olaparib
-
BRCA1 protein, human
-
BRCA1 Protein
-
BRCA2 protein, human
-
BRCA2 Protein
-
Phthalazines